A new oral drug for obesity has delivered double-digit weight loss in a clinical trial, the latest sign that the blockbuster GLP-1 medicines now taken by injection may eventually be available as a simple pill, The Hill reported.
The results
The drug, aleniglipron, is being developed by Structure Therapeutics. In the published mid-stage (Phase 2) trial, patients taking it lost close to 12 percent of their body weight over about 36 weeks, far more than those on a placebo. In the company's broader Phase 2 program, higher doses produced even larger reductions — around 16 percent over a longer period, which Structure has described as the strongest weight-loss result reported so far for an oral GLP-1 drug. As with any company-reported trial data, the figures await fuller scrutiny, and results can change in larger studies.
Why a pill matters
Today's leading obesity and diabetes drugs — semaglutide (sold as Wegovy and Ozempic) and tirzepatide (Zepbound and Mounjaro) — are peptides that must be injected, usually weekly. Aleniglipron is a "small molecule," a type of compound that can be made into a tablet and manufactured at large scale more cheaply than injectables. It can be taken with or without food. If such pills prove effective and safe, they could widen access to treatments that remain expensive and, in places, in short supply.
How it compares
Aleniglipron is not alone. Eli Lilly's oral candidate, orforglipron, has reported weight loss in a similar range in late-stage testing, and the injectables still set the bar: semaglutide produces roughly 14–15 percent weight loss at higher doses, and tirzepatide around 20 percent. Aleniglipron's appeal lies less in beating those figures than in delivering meaningful results in a cheaper, more convenient form.
The caveats
The drug remains experimental and is not approved. Like others in its class, its most common side effects are gastrointestinal — nausea and vomiting — though the company says these were generally manageable and eased over time. Structure has said it plans an end-of-Phase 2 meeting with US regulators and hopes to begin larger Phase 3 trials later in 2026; only those bigger studies can confirm how well the drug works and how safe it is over the long term. And as doctors stress, weight-loss medicines are meant to complement diet and exercise, not replace them — with real-world access ultimately shaped by price and insurance coverage.
